TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business Highlights Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million. Profound’s TULSA-PRO® qualified sales pipeline also continues to grow, and currently stands at 110 new systems being classified within one of the “Verify, Negotiate and Contracting” stages.The Company’s TULSA-PRO installed base stood at 78 as of December 31, 2025 and, due to its strong capital sales pipeline, Profound currently expects to reach approximately 120 installs by the end of 2026.Profound continued to see a wide variety of prostate disease patients treated by its TULSA-PRO customers in the fourth quarter of 2025: 67% were treated for prostate cancer only, 17% were hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”), 13% were salvage, and 3% were men with BPH only;For cancer grade, 5% were GG1, 57% were GG2, 29% were GG3, and 9% were GG4 & GG5;By intention-to-treat, 44% were whole gland; 24% were sub-total but more than half the gland; 24% were hemi-ablations, and 9% were focal therapy; andFor prostate size, 9% were